Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,939,360
  • Shares Outstanding, K 36,807
  • Annual Sales, $ 218,510 K
  • Annual Income, $ 99,940 K
  • 60-Month Beta 0.83
  • Price/Sales 30.52
  • Price/Cash Flow 20.92
  • Price/Book 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate 0.25
  • Low Estimate -1.19
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -1,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.30 +24.56%
on 01/27/20
54.97 -4.15%
on 02/13/20
+6.43 (+13.90%)
since 01/21/20
3-Month
37.52 +40.43%
on 11/22/19
54.97 -4.15%
on 02/13/20
+15.05 (+39.98%)
since 11/21/19
52-Week
30.38 +73.44%
on 09/09/19
63.21 -16.64%
on 03/20/19
+7.01 (+15.35%)
since 02/21/19

Most Recent Stories

More News
REGENXBIO To Host Conference Call on February 26 to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 52.69 (-1.92%)
REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium(TM) 2020

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 52.69 (-1.92%)
Applied Genetic Stock Up on Favorable Eye Therapy Study Data

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

AGTC : 5.35 (-5.98%)
SRPT : 123.98 (+0.72%)
RGNX : 52.69 (-1.92%)
SLDB : 3.29 (-1.79%)
REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update

-- RGX-314 programs for treatment of wet AMD and diabetic retinopathy continue to advance

RGNX : 52.69 (-1.92%)
REGENXBIO Announces Interim Data from Phase I/II Trial of RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 52.69 (-1.92%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

RGNX : 52.69 (-1.92%)
REGENXBIO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 52.69 (-1.92%)
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 52.69 (-1.92%)
Regenxbio: 3Q Earnings Snapshot

ROCKVILLE, Md. (AP) _ Regenxbio Inc. (RGNX) on Tuesday reported a loss of $34.6 million in its third quarter.

RGNX : 52.69 (-1.92%)
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights

-- Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial clinical hold following FDA notification related...

RGNX : 52.69 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade RGNX with:

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

2nd Resistance Point 54.44
1st Resistance Point 53.57
Last Price 52.69
1st Support Level 52.03
2nd Support Level 51.36

See More

52-Week High 63.21
Last Price 52.69
Fibonacci 61.8% 50.67
Fibonacci 50% 46.79
Fibonacci 38.2% 42.92
52-Week Low 30.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar